Biogen is open to lowering the price of its Alzheimer’s drug Aduhelm if it’s more widely prescribed than expected, and the company is negotiating Medicare volume-based pricing agreements, Biogen said Wednesday (June 23) after weeks of backlash over its average $56,000 annual price. Volume-based agreements lower prices as prescriptions rise, but they also encourage more use, which can cause higher overall spending. “We have determined the launch price of ADUHELM based on our belief in the impact of treatment as...